Milestone Pharmaceuticals Inc.
MIST · NASDAQ
Company research
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company headquartered in Montréal, Canada, focused on the development and commercialization of innovative cardiovascular medicines, with a growing U.S. subsidiary based in Charlotte, NC. The company's lead product, CARDAMYST™ (etripamil), is a novel, potent, and short-acting calcium channel blocker delivered as a rapid-onset nasal spray, which received FDA approval and launched commercially in early 2026 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Milestone is also advancing etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR), with a Phase 3 registration trial expected to enroll its first patient in H2 2026, while also pursuing global expansion through an EMA Marketing Authorization Application under review and a China NDA accepted. With approximately $184.2 million in cash and short-term investments as of Q1 2026 and a collaboration agreement with Corxel Pharmaceuticals for commercialization rights, the company is well-positioned to execute on its cardiovascular pipeline under the leadership of CEO Joseph G. Oliveto.
Research reports
Zacks reviews MIST’s Q1 2026 results, highlighting a wider-than-expected adjusted loss per share of 0.20 versus a 0.06 consensus profit, minimal revenue of 0.24 million versus expectations of 0.68 million, and notes that the stock has underperformed the S&P 500 year to date. The article assigns a Zacks Rank #3 (Hold), framing a neutral near-term outlook that will depend on future estimate revisions and the relatively weak Medical – Biomedical and Genetics industry backdrop.
Simply Wall St (syndicated Via SahmCapital) · May 14, 2026Milestone Pharmaceuticals Inc. (NASDAQ:MIST): Is Breakeven Near?Simply Wall St analyzes when MIST might reach profitability, citing consensus from six analysts that the company will post its final loss in 2027 and generate about 14 million of profit in 2028, implying roughly 51 percent annual growth to breakeven. The piece stresses that this aggressive growth path and a debt-to-equity ratio above 2 times make leverage a key risk and urges investors to scrutinize valuation, management quality, and other fundamentals before taking a position.
MarketBeat · March 20, 2026Milestone Pharmaceuticals Q4 2025 Earnings ReportMarketBeat’s AI-generated earnings report summarizes MIST’s Q4 2025 call, emphasizing FDA approval and launch of CARDAMYST as the first new PSVT treatment in about 30 years, encouraging early prescription trends from more than 100 prescribers, and an estimated 200 million pro forma cash balance that management says should fund operations into late 2027. It also flags significant headwinds from the lack of contracted payer coverage, launch-driven increases in commercial spending, and a full-year 2025 net loss of 63.1 million, framing the story as high-potential but dependent on execution and reimbursement traction.
GuruFocus · March 20, 2026Milestone Pharmaceuticals Inc (MIST) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Commercial LaunchGuruFocus highlights the Q4 2025 earnings call, underscoring CARDAMYST’s recent FDA approval, rapid commercial rollout, and a pro forma cash position of roughly 200 million as positives supporting a multi-year launch runway. On the negative side, it points to persistent net losses, ongoing challenges in securing broad insurance coverage, and the early, uncertain stage of real-world uptake as key risks investors should monitor.
Zacks Equity Research (via Finviz) · January 27, 2026All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong BuyIn this note Zacks explains its upgrade of MIST to a Zacks Rank #1 (Strong Buy), arguing that sustained upward revisions to earnings estimates signal improving fundamentals and could drive near-term share price appreciation. The article stresses that the Zacks rating is driven solely by earnings estimate momentum rather than subjective analyst opinion and positions the stock as an attractive candidate for investors seeking names with favorable revision trends, while implicitly acknowledging typical risks around biotech volatility and execution.